These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14552912)

  • 21. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
    DeMarch Z; Giampà C; Patassini S; Martorana A; Bernardi G; Fusco FR
    Neurobiol Dis; 2007 Feb; 25(2):266-73. PubMed ID: 17184995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
    Haik KL; Shear DA; Schroeder U; Sabel BA; Dunbar GL
    Exp Neurol; 2000 Jun; 163(2):430-9. PubMed ID: 10833318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
    Gill JS; Jamwal S; Kumar P; Deshmukh R
    Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.
    Wei H; Qin ZH; Senatorov VV; Wei W; Wang Y; Qian Y; Chuang DM
    Neuroscience; 2001; 106(3):603-12. PubMed ID: 11591460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
    Bensadoun JC; de Almeida LP; Dréano M; Aebischer P; Déglon N
    Eur J Neurosci; 2001 Dec; 14(11):1753-61. PubMed ID: 11860469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease.
    Mishra J; Kumar A
    Pharmacol Rep; 2014 Dec; 66(6):1148-55. PubMed ID: 25443748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
    Kumar A; Chaudhary T; Mishra J
    Eur J Pharmacol; 2013 Nov; 720(1-3):16-28. PubMed ID: 24211676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Olds ME; Jacques DB; Kopyov O
    Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
    Venero JL; Beck KD; Hefti F
    Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid.
    Saliba SW; Vieira EL; Santos RP; Candelario-Jalil E; Fiebich BL; Vieira LB; Teixeira AL; de Oliveira AC
    J Neuroinflammation; 2017 Jan; 14(1):25. PubMed ID: 28143498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minocycline in phenotypic models of Huntington's disease.
    Bantubungi K; Jacquard C; Greco A; Pintor A; Chtarto A; Tai K; Galas MC; Tenenbaum L; Déglon N; Popoli P; Minghetti L; Brouillet E; Brotchi J; Levivier M; Schiffmann SN; Blum D
    Neurobiol Dis; 2005 Feb; 18(1):206-17. PubMed ID: 15649711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
    Verma MK; Goel R; Nandakumar K; Nemmani KVS
    Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
    Sun Z; Xie J; Reiner A
    Exp Neurol; 2002 Jul; 176(1):55-65. PubMed ID: 12093082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum.
    Emerich DF; Winn SR
    Cell Transplant; 2004; 13(3):253-9. PubMed ID: 15191163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
    Schwarz M; Block F; Töpper R; Sontag KH; Noth J
    Ann Neurol; 1992 Sep; 32(3):358-64. PubMed ID: 1329611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity.
    Tassan Mazzocco M; Murtaj V; Martins D; Schellino R; Coliva A; Toninelli E; Vercelli A; Turkheimer F; Belloli S; Moresco RM
    J Neuroinflammation; 2023 Feb; 20(1):34. PubMed ID: 36782185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
    Colle D; Hartwig JM; Soares FA; Farina M
    Brain Res Bull; 2012 Mar; 87(4-5):397-405. PubMed ID: 22245028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.